Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894903 | 0.88 | BTK (0.49) | SYKBRD4BTKFLT3CCNA2 | |
| SCHEMBL10169338 | 0.83 | SYK (0.52) | SYKBRD4BTKFLT3CCNA2 | |
| SCHEMBL894971 | 0.83 | SYK (0.52) | SYKBRD4BTKFLT3CCNA2 | |
| SCHEMBL893537 | 0.81 | SYK (0.52) | SYKBRD4BTKFLT3CCNA2 | |
| SCHEMBL10169167 | 0.75 | SYK (0.56) | SYKBRD4BTKFLT3CCNA2 | |
| SCHEMBL10169371 | 0.74 | STAT6 (0.55) | SYKSTAT6ALK | |
| SCHEMBL25562025 | 0.72 | RET (0.70) | SYKFLT3CDK2ALKCDK4 | |
| SCHEMBL894840 | 0.72 | STAT6 (0.55) | SYKSTAT6JAK2 | |
| SCHEMBL10169425 | 0.72 | FLT3 (0.55) | SYKBRD4BTKFLT3ALK | |
| SCHEMBL894714 | 0.72 | SYK (0.55) | SYKBRD4FLT3CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440204-B1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2440204-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | Bristol-Myers Squibb Company (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| WO-2010144647-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | SYK 22/4885BRD4 271/4885BTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.